IBRXImmunityBio, Inc.Not started yet
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
Relapsed B-Cell Non-Hodgkin Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 20 (planned)
- Started
- Apr 2026
- Main results expected
- Dec 2027
- Fully finished
- Dec 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
ORR in accordance with Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC)
Measured over: Up to 9 months
OS (time from study treatment initiation to death)
Measured over: Up to 89 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07477366 · record last updated 2026-03-17 · checked 2026-11-09 15:42 UTC